Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic XXXX without previous systemic treatment.

@entity1 @entity137 @entity353 @entity5 @entity1295 @entity448 @entity14 @entity204
Ten @entity1 with metastatic @entity14 after resection of the primary @entity5 were treated with high-dose recombinant leukocyte alpha-2 interferon. For a period of 12 weeks the @entity1 received up to 20 X 10(6) IU/m2 im twice weekly. Follow-up varied from 6 to 11 months after stopping treatment. All ten @entity1 were evaluable for @entity5 response and @entity137 . There was one partial response. Nine @entity1 showed growth of metastatic marker lesions. Only three of these @entity1 qualified as having progressive disease (greater than 25% increase in @entity5 mass). The response rate was 10%, with a 95% confidence interval of 0.3%-44.5%. @entity137 proved considerable and consisted of flu-like symptoms, @entity1295 , @entity448 , and @entity353 . Fatigue was the single most important dose-limiting factor. There were no drug-related @entity204 . Three @entity1 died 3, 5, and 7 months after stopping treatment. Median survival was 18 months.
